<DOC>
	<DOCNO>NCT02057003</DOCNO>
	<brief_summary>The purpose study evaluate efficacy tolerability DAA-based regimen clinical practice HIV/HCV-coinfected patient . Hypothesis : The efficacy tolerability DAA-based regimen clinical practice different observe clinical trial HIV/HCV-coinfected patient .</brief_summary>
	<brief_title>Real-life Security Efficacy DAA-based Therapy HCV/HIV-Coinfected Patients</brief_title>
	<detailed_description>Treatment strategy aim achieve sustain virologic response ( SVR ) high priority patient chronic hepatitis C HIV coinfection , since SVR lead dramatic reduction incidence hepatic decompensations mortality set . Until recently , therapy hepatitis C virus ( HCV ) base pegylated interferon ( peg-IFN ) plus ribavirin ( RBV ) . This combination prompt SVR approximately 50 % HCV genotype 1 ( HCV-1 ) -infected patient . Furthermore , costly associate multiple sometimes serious side effect . In set HIV/HCV-1-coinfection , rate SVR even low exceed 25 % clinical practice . Considerable increase SVR achieve recently arrival direct acting antiviral ( DAA ) HCV . Among first new agent protease inhibitor telaprevir ( TVR ) boceprevir ( BOC ) , approve HCV-1 infection . Data obtain clinical trial demonstrate combination peg-IFN/RBV TVR BOC significantly augment SVR rate compare observed peg-IFN plus RBV . As consequence , triple therapy include peg-IFN , RBV plus TVR BOC become standard therapy HCV-1-infected patient set . In addition , number DAAs currently final phase development , case protease inhibitor faldaprevir simeprevir , polymerase NS5B inhibitor sofosbuvir NS5A inhibitor daclatasvir . Although considerable improvement therapy outcome DAA-including regimen give positive prospective , number question solve soon possible . On one hand , information response DAA coinfected population derive clinical trial , often reflect patient management clinical practice . Also , population include clinical trial highly selective may lack high proportion difficult-to-treat individual expect among candidate population , i.e. , fail previous treatment bear compensate cirrhosis . In fact , data derive French cohort CUPIC include HCV-monoinfected , cirrhotic patient , show tolerability efficacy TVR BOC-based treatment low observe pivotal trial . On hand , similar dual therapy include Peg-IFN/RBV , possible response rate safety profile DAAs comparable HCV-monoinfected HIV/HCV-coinfected patient . In context , coinfected population singularity coadministration antiretroviral therapy , may cause drug-drug-interactions decreased tolerability , thus result diminish efficacy . Finally , high relevance identify predictive factor treatment response new DAA-based regimen order individualize treatment decision duration therapy . Due mention , study safety efficacy DAA-based therapy real life condition HIV/HCV-coinfected patient urgently need . Primary objective : - To determine efficacy DAA-based therapy clinical patient chronic hepatitis C HIV coinfection . - To determine security DAA-based therapy clinical patient chronic hepatitis C HIV coinfection . Secondary objective : - Identification predictive factor response DAA-based treatment study population . - Compare security efficacy different DAAs use . - Evaluate on-treatment HCV kinetics different regimen . Scheduled visit : 0 , 1 , 2 , 4 , 8 , 12 , 24 , 36 48 week , well 12 24 week post-treatment . Definition SVR : Undetectable HCV-RNA 24 week schedule end treatment . Definition hepatic fibrosis : - advanced fibrosis : F3 determine liver biopsy 11 kilopascals determine transient elastometry - cirrhosis : F4 determine liver biopsy 14.6 kilopascals determine transient elastometry Variables collect within cohort : - primary outcome variable : SVR ( efficacy study ) % patient discontinue therapy due adverse event ( safety study ) - epidemiological variable : age , sex , interleukin 28B rs12979860 genotype - variable relate hepatitis C virus-infection : infection route , genotype , grade hepatic fibrosis method use determination , baseline Child-Pough-Index , previous hepatic decompensations - treatment-related variable : previous response treatment , dose dose reductions/discontinuations peg-IFN , RBV DAA ( ) , overall severe adverse event , adverse event occur 5 % patient , hepatic decompensations , death , HCV viral load baseline visit - variable relate HIV-infection : Centers Disease Control Prevention ( CDC ) category , HIV viral load , cluster differentiation 4 ( CD4 ) cell count , antiretroviral regimen - analytical variable : aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , platelet , leucocyte , low-density lipoprotein cholesterol , bilirubin , gamma-glutamyltransferase ( GGT ) , alkaline phosphatase , - clinical variable : alcohol intake Quality assurance data check : Data obtain controlled database participate center . Databases monitor controlled query every three month . Descriptive statistic apply order detect transcription error . Source data verification : plan . All grade 3 4 adverse event , well unexpected event , report Andalusian Center Pharmacovigilance ( Centro Andaluz de Farmacovigilancia , www.cafv.es ) . A sample size 230 plan study . Statistical analysis : The outcome variable study achievement SVR , well development severe adverse event follow-up . Descriptive statistical analysis perform order describe cohort . Continuous variable express median [ interquartile range ( IQR ) ] categorical variable number [ percentage ; 95 % confidence interval ( CI ) ] . The association continuous variable SVR frequency patient discontinue therapy analyze use Student 's t-test normal distribution Mann-Whitney U-test otherwise whereas relationship categorical variable determine apply χ2-test Fisher 's test , applicable . Those factor show association univariate analysis p &lt; 0.2 , well biologically possible influence , enter logistic regression order identify independent predictor SVR . The adjusted odds ratio ( AOR ) respective 95 % CI calculate . All p value &lt; 0.05 consider statistically significant . Data analyze use SPSS statistical software package release 19.0 ( SPSS Inc. , Chicago , Illinois , USA ) STATA 9.0 ( StataCorp , College Station , Texas , USA ) . Sample size calculation : Estimating SVR rate 55 % , confidence interval 95 % lost-to-follow-up rate 5 % , minimum 230 patient include order obtain precision 5 % .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Older 18 year HIV infection determine enzymeimmunoassay confirm Western Blot Naïve treatment include DAA Initiation triple therapy include DAA Written inform consent participate study undergo genetic determination Pregnancy Any contraindication administration pegIFN , RBV respective DAA Patients able provide inform consent participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>hepatitis C virus</keyword>
	<keyword>sustain virologic response</keyword>
	<keyword>telaprevir</keyword>
	<keyword>boceprevir</keyword>
	<keyword>simeprevir</keyword>
	<keyword>sofosbuvir</keyword>
	<keyword>daclatasvir</keyword>
	<keyword>paritaprevir</keyword>
	<keyword>pegylated interferon</keyword>
	<keyword>ribavirin</keyword>
	<keyword>direct-acting antiviral</keyword>
	<keyword>dasabuvir</keyword>
	<keyword>ombitasvir</keyword>
	<keyword>ledipasvir</keyword>
	<keyword>velpatasvir</keyword>
	<keyword>grazoprevir</keyword>
	<keyword>elbasvir</keyword>
</DOC>